EVARMED Wins Pre-Seed Pitch Session at Knowledge for Growth in Antwerp, and Secures Spot at Benelux HealthTech Investor Summit

We are proud to share that EVARMED, one of our innovative residents at BioVille, has won the Pre-Seed Pitch Session during the Benelux selection meeting for the HealthTech Investor Summit.

The winning pitch — “EVARVISC™: An Effective and Affordable Platform for Osteoarthritis Treatment in Animals” — was delivered on May 7, 2025, at Knowledge for Growth in Antwerp, one of Europe’s leading life sciences conferences. EVARMED impressed the jury with its innovative approach and clear potential for impact in the veterinary health space.

As a result of this recognition, EVARMED has secured a spot at the Benelux HealthTech Investor Summit, which will take place in Utrecht in December 2025. The summit is a key event for the healthtech ecosystem, bringing together investors, startups, and industry leaders to discuss the future of health technology.

For more information about EVARMED’s products and technology, feel free to contact founder and CEO Artur Henke. He is available for meetings at BioVille and will off course be present at the upcoming Summit in Utrecht.

About EVARMED:

EVARMED develops a new injectable solution for the treatment of osteoarthritis symptoms. The solution replaces pathological synovial fluid with the alternative having the same rheological properties as hyaluronic acid-based products but with greater resistance to joint inflammation. This results in less frequent administration for joint disease patients. The manufacturing process is based on proprietary technology, which additionally is simple and cost-effective, enabling broader access to new viscosupplementation therapy. The product can also be developed as a platform for new advanced regenerative strategies.

Contact info:

Artur Henke
Managing Director
+32 479 07 78 19
arturhenke@evarmed.com